Holes in U.S. Drug Safety Net
Consumer Reports: Drug Approval, Follow-Up 'Flawed'
WebMD News Archive
Drug Industry Reaction continued...
And Trewhitt notes that fewer than 3% of drugs are withdrawn from the market
due to safety concerns -- a rate that hasn't changed since PDUFA took
Laurence B. Gardner, MD, chairman of the department of medicine at the
University of Miami Miller School of Medicine, agrees with most of the points
made by the Consumer Reports article. But he says the FDA's
preapproval process isn't the problem.
"Consumer Reports implies that people at the FDA rush approvals
through and don't look at safety data," Gardner tells WebMD. "But we
are still the safest country in the world when it comes to drug approval. That
being said, there are a lot of issues with our health care system. And current
regulations don't protect the consumer."
After Drug Approval: Patient Beware
When the FDA approves a drug, it sometimes asks the manufacturer to conduct
further safety studies. Consumer Reports notes that in February 2005,
companies agreed to 1,191 such studies. Yet as of September 2005, more than
two-thirds of the studies were still "pending."
The most important drug-safety experiment comes in the years following drug
approval. The subjects of this study: consumers who take the drug.
Preapproval studies enroll no more than a few thousand people -- usually
healthier people than many of those who will take the drug after approval. And
the studies usually last only a few months. Rare side effects, problems for
people with multiple conditions taking multiple other drugs, and long-term side
effects can only be seen in the years following approval.
And that, Lipman says, is where the U.S. system breaks down. Doctors are
supposed to report any side effects that happen. But because there is no
reliable system -- and, Gardner says, because these reports aren't easy to file
-- only a small fraction of side effects actually get reported.
Compounding this problem, Lipman says, is direct-to-consumer advertising.
Ads heavily promote new drugs. Yet there's a drug risk associated with every
drug benefit. And the Consumer Reports article states the ads stress
benefits but don't adequately identify risks. "It is impossible to monitor
all the ads that are out there," Lipman says. "And more ludicrous, the
ad goes into the media, and it takes FDA